Evidence Codex is an educational reference, not medical advice. Many compounds listed are unapproved or have limited human evidence. Read the medical disclaimer.
Evidence CodexResearch, tools and practical guidance
Immunity

Thymosin Alpha-1

← Back to Library
Limited / unverified FDA safety flag Limited / unverified Immunity Longevity
Educational reference only. Read the full disclaimer. The protocols below are not automatically an FDA-approved or clinically verified regimen unless explicitly marked as label-verified or clinical-trial above.

Overview

Route(s): Subcutaneous

Typical vial sizes: 10 mg

Dosing window: Anytime

Receptor / target: MHC-1

Properties: Not stated

Pre-mixed: No

Unverified protocol notes

Standard Protocol

TimeframeDoseNotes
Weeks 1-41.5mg twice weeklyGeneral protocol for immune boosting and maintenance.

Unverified protocol note; not label dosing unless graded otherwise on this page.

Alternative: Acute Infection

TimeframeDoseNotes
Days 1-141.5mg dailyUsed short-term during severe illness, COVID recovery, or high viral load.

Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.

Protocol logic check

Protocol context: Immune protocols are not simple immune 'boosters.' The logic is whether the person needs immune activation, calming, or balance, plus caution around autoimmune disease, active infection, immunosuppressants, and cancer history. Entry context: target (MHC-1); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit.

Independent evidence

Independent safety notes: FDA lists thymosin-alpha-1 with immunogenicity/impurity concerns and inadequate safety information.

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.

Contraindications (limited evidence)

  • Organ transplant recipients: Tα1's restoration and amplification of T-cell mediated immunity and MHC-I upregulation directly counteracts the pharmacological immunosuppression required to prevent allograft rejection; absolute contraindication. Limited / unverified
  • Active autoimmune disorders with Th1-dominant pathology (rheumatoid arthritis, Type 1 diabetes mellitus, multiple sclerosis, psoriatic arthritis): Tα1's Th1-polarizing cytokine activity (IFN-γ, IL-2) could worsen disease activity in conditions already driven by excessive cellular immune responses. Limited / unverified
  • Active autoimmune hepatitis: Tα1 has clinical use in viral hepatitis but in autoimmune hepatitis the mechanism would amplify the T-cell attack on hepatic tissue; contraindicated. Limited / unverified
  • Concurrent systemic corticosteroid or calcineurin inhibitor therapy (tacrolimus, cyclosporine): overlapping immunological mechanisms; Tα1's immune-activating effects will be blunted and the interaction could produce unpredictable immune reconstitution patterns. Limited / unverified
  • Known hypersensitivity to Thymosin Alpha-1 or any formulation excipients. Limited / unverified
  • Pregnancy: maternal immune activation carries theoretical risk of fetal immune effects; no clinical safety data in pregnancy. Limited / unverified
  • Breastfeeding: no established safety data. Limited / unverified
  • Active graft-versus-host disease (GVHD): T-cell activation by Tα1 in a subject already experiencing immune-mediated tissue destruction from donor T-cells could dramatically worsen GVHD. Limited / unverified
  • Concurrent immunostimulatory biologic therapy (IL-2, IFN-α/β/γ): additive cytokine stimulation may produce cytokine excess syndromes. Limited / unverified

Side effects (limited evidence)

  • Mild injection site redness and erythema: the most commonly reported adverse effect across all clinical trials and post-marketing surveillance; localized; self-resolving; consistent with subcutaneous peptide administration. Limited / unverified
  • Temporary flu-like symptoms: low-grade fever, mild myalgia, fatigue, chills in the first 1-3 days of a new cycle; reflects the acute activation of innate and adaptive immune responses; typically self-limiting within 48-72 hours. Limited / unverified
  • Transient lymphopenia before lymphocyte expansion: a paradoxical early finding in some clinical data; lymphocyte redistribution (trafficking to lymph nodes) precedes the measured increase in circulating lymphocyte counts. Limited / unverified
  • Mild headache: uncommon; reported in a minority of subjects in clinical trial data; transient. Limited / unverified
  • Transient fatigue: moderate; related to the metabolic demand of immune activation; resolves as immune competence is restored. Limited / unverified
  • Potential autoimmune flare in susceptible individuals: subjects with underlying but undiagnosed autoimmune tendencies may experience symptom emergence; the Th1 polarization activity is the mechanistic driver. Limited / unverified
  • Nausea: rare; mild; reported infrequently in clinical trial safety data. Limited / unverified
  • Local induration at injection site: uncommon; minor subcutaneous tissue reaction; resolves spontaneously. Limited / unverified
  • Acute rejection reaction in transplant recipients (if used contraindication is violated): the most serious potential consequence; not a side effect in standard use but the catastrophic outcome of use in the absolutely contraindicated transplant population. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

ThymalinVIP (Vasoactive Intestinal Peptide)KPVPNC-27KLOW (BPC-157 + TB-500 + KPV + GHK-Cu)tri-heal-blend

Reported contraindicated combinations:

None listed.

Sources